CASPA: CArdiac Sarcoidosis in PApworth

CASPA (CArdiac Sarcoidosis in PApworth): Improving the Diagnosis of Cardiac Disease in Patients With Pulmonary Sarcoidosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03599414

Acronym

CASPA

Enrollment

104

Registered

2018-07-26

Start date

2017-06-29

Completion date

2023-03-08

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Sarcoidosis, Interstitial Lung Disease, Pulmonary Sarcoidosis

Keywords

sarcoidosis, cardiac, MRI, Echocardiography, pulmonary, cytokine

Brief summary

Sarcoidosis is a disease of unknown cause which affects adults of all ethnic backgrounds. Clumps of tissue called granulomas develop primarily in the lungs, but can damage other organs, especially the heart. Anecdotal evidence from autopsy studies suggests the heart is affected in up to 68% of patients, but there is much uncertainty about this figure. If undetected and untreated, it can lead to serious complications or even sudden death. The current recommendation is to perform heart tracings (ECG s) on all patients, but this detects fewer than half of those with heart involvement. Blood markers traditionally used to diagnose heart disease are unreliable, meaning there is no simple blood test in use. The investigators propose a study with three aims. Firstly, identify the true prevalence of heart disease by performing Magnetic Resonance Imaging (MRI) scans on a group of patients with newly diagnosed lung sarcoidosis. Those found to have heart disease will have specialist (but routine) electrical heart tests. Secondly, (and perhaps the most immediate and clinically relevant) to identify the best method of diagnosing heart involvement using a combination of three simple tests: advanced ECG, 24-hour continuous ECG and a new type of computerised ultrasound scan. Thirdly, to identify proteins in the blood that could be used to develop a simple blood test for heart involvement in patients with lung sarcoidosis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Newly referred adult patients with pulmonary sarcoidosis and diagnosis made at multidisciplinary meeting as per current joint BTS/ATS guidance * Patient may be on ≤10mg prednisolone at time of recruitment (if already started at another site prior to referral). * Able to give informed consent and able to comply with protocol * ≥\>18 yrs

Exclusion criteria

* History of other cardiac disease (e.g. coronary artery disease)cardiac surgery or previous myocardial infarction (MI) * Inability to give informed consent * \<18 yrs * Patient may be on \>10mg prednisolone at time of recruitment (if already started at another site prior to referral). * On non-steroidal medication including methotrexate * Pregnancy * Alcoholism * Illicit drug abuse

Design outcomes

Primary

Measure	Time frame	Description
The prevalence of cardiac sarcoidosis in patients with pulmonary sarcoidosis	on Day 1	The prevalence of cardiac sarcoidosis in patients with pulmonary sarcoidosis

Secondary

Measure	Time frame	Description
Cytokine and Proteomic profiling	after 1 year	Completion of cytokine and proteomic profiling of patients with pulmonary sarcoidosis
Diagnosis of cardiac sarcoidosis	on Day 1	Diagnosis of cardiac sarcoidosis by combining signal averaged ECG, speckle tracking echocardiography and 24 hour holter monitoring

Countries

United Kingdom

Outcome results